Papillary Thyroid Carcinoma in Children: Clinicopathological Profile and Outcomes of Management
Overview
Authors
Affiliations
Background: We aim to analyze the clinicopathological profile and outcomes of management for children with papillary thyroid carcinoma (PTC).
Methods: Relevant clinical data of children ≤ 18 years of age managed for PTC between January 2006 and July 2018 as well as details of their follow-up till December 2019 were retrospectively collected and analyzed.
Results: There were 82 children with PTC that were managed during the study period. At presentation, 39 (47.6%) had cervical lymphadenopathy, while 9 (11%) had systemic metastasis. Majority of patients 39 (47.6%) underwent total thyroidectomy with a selective neck dissection, while total thyroidectomy alone was performed in 26 (31.7%). Following surgery, hypocalcemia was seen in 39 (47.6%): 28 (34.1%) were temporary, while 11 (13.4%) were permanent. Twenty-eight (34%) developed persistent disease after surgery and I therapy. Significant risk factors for persistence and metastatic disease were metastatic cervical lymph node at presentation (p = 0.002) and tumor size (p = 0.014), respectively. The mean duration of follow-up was 60.3 (range 12-150) months with a mean overall disease-free survival of 60 months (95% CI 57.11, 77.95).
Conclusion: Children with papillary thyroid cancers present with aggressive disease, 47.6% with cervical nodal metastasis and 11% with distant metastasis in this cohort. The rate of post-thyroidectomy hypocalcemia in this study is substantial, and efforts to reduce it are actively being pursued. The presence of metastatic cervical lymph node at presentation (p = 0.002) and tumor size (p = 0.014) were the only significant risk factors for persistent and metastatic disease, respectively, in this study.
Du R, Zhang Y, Kou J, Li J, Sui C, Zhang D Front Endocrinol (Lausanne). 2024; 14:1298036.
PMID: 38274235 PMC: 10808709. DOI: 10.3389/fendo.2023.1298036.
Hay I, Lee R, Reading C, Pittock S, Sharma A, Thompson G J Endocr Soc. 2023; 7(7):bvad065.
PMID: 37388573 PMC: 10306272. DOI: 10.1210/jendso/bvad065.
Janus D, Wojcik M, Taczanowska-Niemczuk A, Kiszka-Wilkojc A, Kujdowicz M, Czogala M Front Endocrinol (Lausanne). 2023; 14:1170971.
PMID: 37274328 PMC: 10233204. DOI: 10.3389/fendo.2023.1170971.
Lei Y, Zhao X, Feng Y, He D, Hu D, Min Y Cancer Control. 2023; 30:10732748231155701.
PMID: 36744396 PMC: 9905023. DOI: 10.1177/10732748231155701.
Jie Y, Ruan J, Cai Y, Luo M, Liu R Heliyon. 2023; 9(1):e12828.
PMID: 36704282 PMC: 9871215. DOI: 10.1016/j.heliyon.2023.e12828.